ClinicalTrials.gg
RecruitingNCT05977231Updated Aug 4, 2023

Efficacy of Conservative Treatments for Urinary Incontinence in Women

An observational study in Urinary Incontinence, sponsored by Mackay Medical College. Recruiting at 1 site in Taiwan. Open to female participants aged 20 Years to 100 Years. Per ClinicalTrials.gov, last updated 2023-08-04.

Sponsored by Mackay Medical College · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
60
Ages
20 Years to 100 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Urinary Incontinence with a site in Taiwan — 2 open to participants now, 2 under way, none of them phase 3. Urinary Incontinence · Taiwan.

Started
2023
with 3 others
Observational
3 of 13
1 open now
Registered
9th of 13
by date
Lead sponsor
1 of 13
Mackay Medical College

Among the 13 studies in Urinary Incontinence with a site in Taiwan, this one is one of 4 that started in 2023, is one of 3 observational ones, and was the 9th registered.

Urinary Incontinence

988 studies on the registry are indexed under Urinary Incontinence; 184 are open to participants now.

Browse Urinary Incontinence studies →

Open to participants now

2 of the 13 studies in Urinary Incontinence with a site in Taiwan are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 113 Urinary Incontinence studies recruiting now, 63 (56%) set no upper age limit and 35 (31%) stop at 75 or younger; 15 take children under 18; 28 take healthy volunteers.

This study: 20 Years to 100 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Urinary Incontinence with a site in Taiwan, or all of them as a file.
02

Study summary

To conduct a retrospective study to examine the effect of these conservative treatments to the symptoms and quality of life of patients with urinary incontinence. The investigators will use both subjective and objective assessment parameters, such as self-report symptoms, bladder diary, pad test and urodynamic study to access the improvement.

Read the detailed description

Urinary incontinence is a common problem among women. The main types include stress incontinence, urge incontinence, and overflow incontinence. Other underlying pathology, such as cancer or neurologic disease can also cause urinary incontinence. To limit the medical expenses and possible complications of surgical treatment, the current treatment guidelines recommend conservative treatment as the first choice. According to American Urological Association (AUA)/Society of Urodynamics, Female Pelvic Medicine \& Urogenital Reconstruction (SUFU) guidelines, the first-line treatment for non-neurologic overactive bladder should be behavioral therapy, such as bladder training, water restriction, and pelvic floor muscle training, physiological feedback, pessary, etc. Bladder training aims to increase the time interval between voids, and to increase the bladder capacity by self-adjusted schedules. Pelvic floor muscle training strengthens the pelvic floor muscles to provide urethral support to prevent urine leakage and suppress urgency. There is strong evidence that pelvic floor muscle training is beneficial for stress urinary incontinence.

The second-line treatment is medication, including anticholinergic drugs and ß3 adrenoceptor-acting agents. Anticholinergic drugs can reduce bladder detrusor contraction, and ß3 adrenoceptor-acting agents can relax the detrusor and increase bladder capacity.

03

Conditions studied

  • Urinary Incontinence

Browse trials for

04

Who can participate

Ages eligible
20 Years to 100 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Diagnosed at Mackay Memorial Hospital, the adult female patient was clinically assessed and diagnosed with urinary incontinence. Non-surgical treatments were administered, followed by subsequent monitoring and follow-up.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult female patient diagnosed with urinary incontinence through clinical assessment
  • Diagnosed at Mackay Memorial Hospital and underwent non-surgical treatment and subsequent follow-up.

Exclusion criteria

Exclusion Criteria:

  • Choosing invasive or surgical treatment options (such as bladder botulinum toxin injection, urethral sling surgery).
  • Unable to comply with regular follow-up for at least one year.
  • Pregnant women
  • Patients with a history of neuromuscular disorders.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • Bladder training (BT)

    Data obtained before and after the training.

    Procedure: BT

  • biofeedback-assisted pelvic floor muscle training (bPFMT)

    Data obtained before and after the training.

    Procedure: bPFMT

  • intra-vaginal electric stimulation (iVES)

    Data obtained before and after the training.

    Procedure: iVES

  • BT+bPFMT

    Data obtained before and after the training.

    Procedure: BT + bPFMT

  • BT+iVES

    Data obtained before and after the training.

    Procedure: BT + iVES

  • bPFMT+iVES

    Data obtained before and after the training.

    Procedure: bPFMT + iVES

Interventions

  • ProcedureBT

    A program of BT (including exercise and muscle training)

  • ProcedurebPFMT

    A bPFMT program at home

  • ProcedureiVES

    An iVES program at home

  • ProcedureBT + bPFMT

    Combination of BT and bPFMT

  • ProcedureBT + iVES

    Combination of BT and iVES

  • ProcedurebPFMT + iVES

    Combination of bPFMT and iVES

06

What researchers measure

Primary outcomes

  1. Urodynamic study (intravesical pressure)

    intravesical pressure (cmH2O)

    Time frame: form the baseline to the post-treatment measurement (about 6 month post)

  2. Urodynamic study (abdominal pressure)

    abdominal pressure (cmH2O)

    Time frame: form the baseline to the post-treatment measurement (about 6 month post)

  3. Urodynamic study (detrusor pressure)

    detrusor pressure (cmH2O)

    Time frame: from the baseline to the post-treatment measurement (about 6 month post)

  4. Urodynamic study (Infused volume)

    infused volume (ml)

    Time frame: from the baseline to the post-treatment measurement (about 6 month post)

  5. Urodynamic study (voided volume)

    voided volume (ml)

    Time frame: from the baseline to the post-treatment measurement (about 6 month post)

  6. Pad test

    The weight of Pad (g) before and after testing

    Time frame: from the baseline to the post-treatment measurement (about 6 month post)

  7. Bladder diary (voiding frequency)

    the daily voiding frequency (times)

    Time frame: from the baseline to the post-treatment measurement (about 6 month post)

  8. Bladder diary (voiding volume)

    the daily voiding volume (ml)

    Time frame: from the baseline to the post-treatment measurement (about 6 month post)

  9. Questionaire (UDI-6)

    The urogenital distress inventory-6 (UDI-6)

    Time frame: from the baseline to the post-treatment measurement (about 6 month post)

  10. Questionaire (IIQ-7)

    incontinence impact questionnaire-7 (IIQ-7)

    Time frame: from the baseline to the post-treatment measurement (about 6 month post)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Denisenko AA, Clark CB, D'Amico M, Murphy AM. Evaluation and management of female urinary incontinence. Can J Urol. 2021 Aug;28(S2):27-32. PubMed 34453426 ↗
  • Wallace SL, Miller LD, Mishra K. Pelvic floor physical therapy in the treatment of pelvic floor dysfunction in women. Curr Opin Obstet Gynecol. 2019 Dec;31(6):485-493. doi: 10.1097/GCO.0000000000000584. PubMed 31609735 ↗
  • Aoki Y, Brown HW, Brubaker L, Cornu JN, Daly JO, Cartwright R. Urinary incontinence in women. Nat Rev Dis Primers. 2017 Jul 6;3:17042. doi: 10.1038/nrdp.2017.42. Erratum In: Nat Rev Dis Primers. 2017 Nov 16;3:17097. doi: 10.1038/nrdp.2017.97. PubMed 28681849 ↗
  • Lin HY, Tsai HW, Tsui KH, An YF, Lo CC, Lin ZH, Liou WS, Wang PH. The short-term outcome of laser in the management of female pelvic floor disorders: Focus on stress urine incontinence and sexual dysfunction. Taiwan J Obstet Gynecol. 2018 Dec;57(6):825-829. doi: 10.1016/j.tjog.2018.10.010. PubMed 30545535 ↗

Individual participant data

Plan to share: No — For we uncertain if this might violate personal information laws in our country.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Dec 2023, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2023
First posted
Aug 4, 2023
StartActual
Jan 1, 2023
Primary completionEst.
Dec 31, 2023
CompletionEst.
Dec 31, 2028
Last update
Aug 4, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05977231
Lead sponsor
Mackay Medical College
Responsible party
Chin-Tsung Shen (The Office of Research and Development staff, Mackay Medical College) — Principal investigator
First posted
Aug 4, 2023
Start date
Jan 1, 2023
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Aug 4, 2023

Study contacts

Hui-Hsuan Lau, M.D.
Contact
huihsuan1220@gmail.com
+886-975-835928
Hui-Hsuan Lau, M.D.
study chair · Department of Ear, Nose, and Throat, MacKay Memorial Hospital, Taipei, Taiwan

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion